Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been observed in several systems to correlate with a decreased ability of the insulin receptor to tyrosine-phosphorylate this endogenous substrate and to inhibit its subsequent association with phosphatidylinositol 3-kinase. In the present studies we have examined the potential role of the mitogen-activated protein (MAP) kinase in the increased serine phosphorylation of IRS-1 observed in human embryonic kidney cells treated with an activator of protein kinase C, phorbol 12-myristate 13-acetate. First, recombinantly produced kinase was shown to phosphorylate intact IRS-1 in a way that decreased the ability of isolated insulin receptor to phosphorylate the tyrosines recognized by the SH2 domains of the phosphatidylinositol 3-kinase. Second, an inhibitor of MAP kinase activation, PD98059, blocked the phorbol 12-myristate 13-acetateinduced inhibition of the insulin-stimulated increase in IRS-1 associated phosphatidylinositol 3-kinase. Third, activation of MAP kinase in intact cells via a regulatable upstream kinase, a RAF:estrogen receptor construct, could also inhibit the insulin-stimulated increase in IRS-1-associated phosphatidylinositol 3-kinase. Fourth, an in gel kinase assay showed that MAP kinase was the primary renaturable kinase in cell extracts capable of phosphorylating an IRS-1 fusion protein. Finally, IRS-1 was found to associate in coprecipitation studies with endogenous MAP kinase. These studies implicate MAP kinase as one of the kinases capable of phosphorylating and regulating IRS-1 tyrosine phosphorylation.
Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been observed in several systems to correlate with a decreased ability of the insulin receptor to tyrosine-phosphorylate this endogenous substrate and to inhibit its subsequent association with phosphatidylinositol 3-kinase. In the present studies we have examined the potential role of the mitogen-activated protein (MAP) kinase in the increased serine phosphorylation of IRS-1 observed in human embryonic kidney cells treated with an activator of protein kinase C, phorbol 12-myristate 13-acetate. First, recombinantly produced kinase was shown to phosphorylate intact IRS-1 in a way that decreased the ability of isolated insulin receptor to phosphorylate the tyrosines recognized by the SH2 domains of the phosphatidylinositol 3-kinase. Second, an inhibitor of MAP kinase activation, PD98059, blocked the phorbol 12-myristate 13-acetateinduced inhibition of the insulin-stimulated increase in IRS-1 associated phosphatidylinositol 3-kinase. Third, activation of MAP kinase in intact cells via a regulatable upstream kinase, a RAF:estrogen receptor construct, could also inhibit the insulin-stimulated increase in IRS-1-associated phosphatidylinositol 3-kinase. Fourth, an in gel kinase assay showed that MAP kinase was the primary renaturable kinase in cell extracts capable of phosphorylating an IRS-1 fusion protein. Finally, IRS-1 was found to associate in coprecipitation studies with endogenous MAP kinase. These studies implicate MAP kinase as one of the kinases capable of phosphorylating and regulating IRS-1 tyrosine phosphorylation.
Insulin receptor substrate-1 (IRS-1), 1 a major endogenous substrate of the insulin receptor kinase, undergoes tyrosine phosphorylation upon insulin stimulation, after which it serves as a docking protein for a number of Src homology (SH) 2 domain containing proteins such as Grb2, Syp, Nck, and two isoforms of the regulatory subunit of PI 3-kinase (p85) (1, 2) .
Binding of tyrosine-phosphorylated IRS-1 to p85 leads to a 3-5-fold stimulation of PI 3-kinase activity (3) , an increase in the PI 3,4-bisphosphate and 3,4,5-trisphosphate in the cell (4) , and possibly through the stimulation of the Ser/Thr kinase AKT/PKB (5) , to the final effects of insulin such as stimulation of glucose uptake and glycogen synthesis. Although IRS-1 contains at least 20 potential tyrosine phosphorylation sites (1, 2) , one (tyrosine 608) appears to be a principal site of interaction with the SH2 domain of PI 3-kinase, while three others (tyrosines 460, 939, and 987) play additional roles (6) . Under several conditions resulting in cellular insulin resistance, such as activation of protein kinase C (PKC) (7, 8) , addition of the Ser/Thr phosphatase inhibitor okadaic acid (9) , activation of cellular stress pathways by tumor necrosis factor and other cytokines (10 -12) , a decrease in insulin-stimulated tyrosine phosphorylation of IRS-1 is observed; however, the mechanism(s) by which these inhibitory effects occur has been difficult to elucidate.
Under many of the conditions mentioned above, Ser/Thr kinases are activated, and one hypothesis has been that increased serine phosphorylation of IRS-1 can result in subsequent inhibition of its tyrosine phosphorylation by the insulin receptor (9 -12) . In fact, IRS-1 contains numerous serine phosphorylation sites and is extensively serine-phosphorylated after insulin stimulation, possibly in part by casein kinase II (13, 14) . In addition, IRS-1 contains 4 serines in the motif, Pro-XSer-Pro, a consensus sequence recognized by members of the MAP kinase family (15) . All 4 of these serines are located exactly 4 amino acids downstream of potential tyrosine phosphorylation sites, and one (serine 612) is close to the major PI 3-kinase binding site, tyrosine 608. Moreover, serine 612 is phosphorylated upon PKC activation in a human kidney fibroblasts cell line (293 cells) (16) , and a mutant IRS-1 lacking this site is less inhibited by PKC activation. Since p42 and p44 MAP kinase activity are known to be stimulated by PKC (via the sequential activation of Raf and the MAP kinase kinase I (MEK1)), these kinases are potential candidates for mediating the phosphorylation of IRS-1 at this site (17) (18) (19) . Two other subfamilies of MAP kinases, the stress-activated protein kinases (also called c-Jun N-terminal kinases) and p38 MAP kinase, are activated by a number of conditions causing a cellular stress response, such as osmotic shock, ultraviolet irradiation, transcriptional and translational inhibitors, and inflammatory cytokines (17) (18) (19) . Thus, some of the same factors known to activate the various members of the MAP kinase family have been implicated in cellular insulin resistance.
Previous studies have shown that PKC activation, both in CHO cells tranfected with PKC␣ (CHO/PKC cells) and in 293 cells stably expressing IRS-1 (293/IRS), results in decreased insulin-stimulated tyrosine phosphorylation of IRS-1 and a decrease in its subsequent association with PI 3-kinase in whole cells. In the same studies, no decrease in IR autophos-phorylation or in vitro kinase activity was observed (7, 16) . More recently this inhibition was found to correspond to the activation of a cytosolic serine kinase capable of phosphorylating IRS-1 and a synthetic peptide containing the sequence corresponding to serine 612 (16) . The presence of a phosphate on serine 612 in this peptide also appears to inhibit the ability of the IR to phosphorylate the tyrosine in this peptide which corresponds to tyrosine 608 in IRS-1 (16), the major PI 3-kinase binding site.
The present studies were directed at identifying the Ser/Thr kinase responsible for phosphorylating IRS-1 and this IRS-1 peptide after phorbol 12-myristate 13-acetate (PMA) stimulation. Since the serine phosphorylation site in this peptide corresponds to a MAP kinase consensus phosphorylation site, we focused on the possibility that MAP kinase was responsible for this activity. A variety of approaches were utilized to investigate this question, including the use of a specific inhibitor of the upstream regulator of MAP kinase, MEK1, in vitro phosphorylation of IRS-1 and its peptide by recombinant ERK2, as well as expression of a regulatable Raf so that MAP kinase could be independently activated in cells.
EXPERIMENTAL PROCEDURES

Materials
Monoclonal anti-Myc 9E10 antibody for immunoprecipitation was purchased from Berkeley Antibody Co. Monoclonal anti-p85 hybridoma supernatant was a gift from Dr. Kozui Shii. Polyclonal anti-IRS-1 (C terminus) antibody for Western blot analysis was purchased from Upstate Biotechnology Inc. Anti-phosphotyrosine antibody (RC20) coupled to horseradish peroxidase was obtained from Transduction Laboratories. Protein G-agarose was purchased from Pharmacia Biotech Inc. The antibody to active MAP kinase was from Promega. A polyclonal antisera to the estrogen receptor (HC-20) was purchased from Santa Cruz Biochemicals. SB203580 was a gift of Dr. John Lee, SmithKline Beecham. [␥-32 P]ATP was purchased from DuPont NEN. Purified PI was obtained from Avanti Biochemicals. Immobilon membranes were obtained from Bio-Rad. PMA was purchased from LCI. Plasmid preparation and DNA purification kits were purchased from QIAGEN. pcDNAzeo plasmid was obtained from INVITROGEN. Enzymes for molecular biology were obtained from New England Biolabs and Life Technologies, Inc. SDS-PAGE reagents were purchased from Life Technologies, Inc. IRS-1 peptides were synthesized by the Beckman PAN facility. All other reagents were purchased from Sigma.
Methods
Plasmid Construction and Bacterial Protein Expression-For the transient transfection studies, the 2-kilobase pair insert of pBABE⌬Raf:ER (a gift of Dr. Martin McMahon, DNAX) (20) was subcloned into pcDNAzeo. To make the GST-IRS-1 fusion protein, an EcoRI fragment from pucIRS (16) containing nucleotides 2112-3283 of IRS-1 plus a 17 nucleotide stretch of the puc18 polylinker was cloned into pGEX4T2 (Invitrogen) to give pGEX-IRS-1B/R. The expressed fusion protein is approximately 70 kDa, corresponding to GST and residues 509 -890 of IRS-1. For the Far Western studies, a 1-liter culture of pGEX-p852SH2 (21) (a gift of Dr. Edgar Wood, Burroughs Welcome) in BL21 cells was induced with 0.4 mM isopropyl-1-thio-␤-D-galactopyranoside for 3 h at 30°C. The cells were harvested, resuspended in PBS supplemented with 2 mM EDTA, 1 mM dithiothreitol, and protease inhibitors, sonicated on ice for a total of 3 min after which 1% Triton X-100 was added. Lysed cells were centrifuged for 20 min at 13,000 rpm, and supernatants were filtered through a 0.25-m filter and incubated with glutathione agarose at 4°C for 2 h. GST-p85 was eluted with 1 ml of 15 mM glutathione and stored at 4°C. The final concentration of eluted protein was approximately 800 g/ml. For in-gel kinase assays, 1-liter cultures of BL21 cells containing pGEX-IRS-1B/R were induced with 1 mM isopropyl-1-thio-␤-D-galactopyranoside for 2 h at 30°C. Cells were harvested, resuspended in 6 M urea, PBS, and centrifuged for 20 min at 13,000 rpm. The supernatants were dialyzed overnight against PBS to remove urea. They were then incubated with glutathione agarose for 2 h at 4°C. The GST-IRS-1B/R was eluted with 2 ml of 40 mM glutathione and stored at 4°C. The final concentration of eluted protein was approximately 500 g/ml.
Cell Culture and Transfections-Epitope-tagged IRS-1 was transiently coexpressed with pcDNA-Raf:ER or pcDNAzeo (vector control) in 293T (a 293 line which constitutively expresses T antigen) or pBABERaf:ER/puro was stably expressed in 3T3-L1 cells by retroviral infection (16) . Both cell lines were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (FCS). Transient transfections were performed in 293T cells using the calcium phosphate precipitation method as described previously (16) . Fourteen to 17 h after transfection, cells were incubated in Dulbecco's modified Eagle's medium containing 10% FCS for 24 h, at which point they were split 1:2 or 1:4 and grown for an additional 24 -36 h. Retroviral infections were performed as described elsewhere (22) . Cells were split 1:10 and 1:20 in Dulbecco's modified Eagle's medium/FCS containing 1.5 g/ml puromycin 48 h after infection, and after 7 days surviving cell populations were screened for expression of Raf:ER by Western blotting with antibodies to the estrogen receptor. Positive cell populations were identified and maintained in Dulbecco's modified Eagle's medium, 10% FCS.
In Situ Tyrosine Phosphorylation of IRS-1 and p85 Binding-Tencm dishes of 293 cells stably expressing IRS-Myc (293/IRS) were serumstarved for 16 h and then treated with or without 1.6 M PMA for 20 min followed by 5 min in the presence or absence of 1 M insulin. For the 3T3-L1-Raf:ER cells, they were differentiated as described, serumstarved for 16 h, followed by treatment with or without 1 M 4-hydroxytamoxifen (4-HT) for 2 h, then incubated for 5 min in the presence or absence of 1 M insulin. 293T cells, transiently transfected with IRS-Myc and pcDNA-Raf:ER as described above, were serum-starved for 16 h and then treated with or without 1 M 4-HT for 1 h, followed by treatment with or without 1 M insulin. Cells were washed one time in 50 mM Hepes, pH 7.6, 150 mM NaCl (HBS) and lysed on ice for 20 min in lysis buffer A (50 mM Hepes, pH 7.6, 150 mM NaCl, 1% Triton X-100, 2 mM vanadate, 100 mM NaF, 2.5 mM sodium pyrophosphate, 10 mM EDTA, 0.25 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin), and adsorbed with either anti-Myc or anti-p85 antibodies bound to protein G agarose to isolate total IRS-1 or p85-associated IRS-1, respectively. After 3 h at 4°C, the agarose beads were washed two times in WGBT (50 mM Hepes, pH 7.6, 150 mM NaCl, 0.1% bovine serum albumin, and 0.1% Triton X-100) and one time in phosphate-buffered saline, and the bound proteins were eluted by boiling in gel loading buffer (40% glycerol, 1% SDS, 50 mM Tris, pH 6.8, 1 M dithiothreitol). After separation of the samples by SDS-PAGE and transfer to Immobilon, the membrane was probed with an anti-phosphotyrosine antibody coupled to horseradish peroxidase and analyzed by enhanced chemiluminescence. Membranes were stripped of anti-phosphotyrosine antibodies by incubation in 2% phenyl phosphate in Tris/NaCl for 3 h, washed two times, and reprobed with either the monoclonal anti-Myc antibody, a polyclonal antibody to p85, or a polyclonal antibody to IRS-1, followed by visualization by secondary antibodies coupled to alkaline phosphatase and development with chromagenic substrates. Quantitation of the bands was performed by scanning and the amount of p85 associated or tyrosine phosphorylated IRS-1 was normalized to the total amounts of p85 or IRS-1 present in each lane and fold-insulin stimulation was calculated as the level of tyrosine phosphorylation in the immunoprecipitates from insulin-treated cells versus untreated cells.
PI 3-Kinase Activity-293 cells stably expressing IRS-Myc were serum-starved for 16 h and first treated with or without 50 M PD98059 (a gift of Dr. Alan Saltiel, Warner Lambert), followed by treatment with or without 1 M PMA, and then incubated with or without 1 M insulin. Cells were lysed (20 mM Tris, pH 8.0, 137 mM NaCl, 1% Nonidet-P40, 10% glycerol, 1 mM CaCl 2 , 1 mM MgCl 2 , 200 M vanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml aprotinin), and the lysates were immunoprecipitated with anti-Myc antibodies bound to protein G-agarose. The beads were washed, incubated with 10 g of PI and 5 Ci of [␥-
32 P]ATP for 5 min at room temperature, the reaction was terminated, and the phosphorylated PI was analyzed by thin layer chromatography as described previously (7) . Bands were excised from the plates and counted.
In Vitro Phosphorylation of IRS-1 by Recombinant ERK2-293 cells expressing IRS-Myc were serum-starved 16 h and lysed in buffer A. Cell lysates were immunoprecipitated with anti-Myc antibodies bound to protein G-agarose. After 2 h, beads were washed two times in WGBT and one time in HBS, 0.1% Triton X-100 (WGB). Either 1 g of activated recombinant ERK2, activated with 0.25 g of recombinant MEK in kinase buffer MEK (10 mM Hepes, 10 mM MgCl 2 , 100 M ATP, and 1 mg/ml bovine serum albumin) for 1 h at 30°C, or 1 g of unactivated ERK2 was added in 100 l of MAP kinase buffer (final concentrations: 20 mM Hepes, 12 mM MgCl 2 , 10 M ATP and 2 Ci of [␥-32 P]ATP) for 30 min at 24°C. Beads were washed twice in 1 M NaCl, 100 mM Tris, pH 7.6, and once in PBS, boiled in gel loading buffer, and analyzed on 7.5% SDS-PAGE, followed by transfer to Immobilon. Blots were probed with antibody to IRS-1; bands were excised and counted.
Phosphorylation by IR and Far Western Blots with GST-p85-IRS-1
was phosphorylated with ERK2 as described above, except that 1 mM cold ATP was added to MAP kinase buffer in place of the radioactive ATP. IR was prepared from one confluent 10-cm plate of 293 cells treated with 1.6 M PMA, by incubation of the lysates with 60 l of wheat germ agglutinin coupled to agarose and eluted with 60 l of 0.3 M N-acetylglucosamine as described previously. Either 10 l of eluted IR, or 10 l of the elution buffer, were added to each IRS-1 sample in the presence of 1 M insulin, 1 mM ATP, 10 mM MgCl 2 , and 10 mM MnCl 2 and incubated at room temperature for 20 min. Beads were washed three times in WGB followed by one wash in PBS, and IRS-1 was eluted and analyzed on 7.5% SDS-PAGE, followed by transfer to Immobilon. Fifty g of GST-p85 were preincubated with 100 g of anti-GST antibody. After blocking, the membrane was incubated in a 10-ml solution containing a 1:500 dilution of the GST-p85/antibody complex in 100 mM Tris, pH 7.6, 50 mM NaCl, 0.2% Tween, 3% bovine serum albumin, 1% FCS, and 5% milk for 2 h at room temperature. The mixture was then incubated with secondary antibody coupled to horseradish peroxidase and developed by enhanced chemiluminescence as described for antiphosphotyrosine blots. Blots were stripped with 200 mM glycine, pH 3.0, for 10 min, washed with TBS three times for 30 min each, and reprobed with anti-IRS-1 antibody. Quantitation was performed by scanning, and values were normalized to the total IRS-1 present in each lane.
Phosphorylation of IRS-1 Peptide by Cytosolic
Lysates and ERK2-293T cells, transfected with IRS-Myc and ER-Raf, were serum-starved for 16 h, followed by treatment with or without 1 M 4-HT for 1 h. Cells were scraped into 150 l of buffer A (20 mM Tris, pH 7.6, 220 mM sucrose, 10 mM EDTA, 10 mM Na-PP i , 2 mM Na-vanadate, 10 mM NaF, 10 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 250 M okadaic acid), homogenized by 15 strokes, sonicated three times for 15 s, and centrifuged at 200,000 ϫ g for 20 min. The supernatants (the cytosol) were removed, and Hepes (60 mM, final concentration) and MgCl 2 (10 mM) were added. Sixty l of cytosol were added to reaction tubes containing 100 M IRS-1 peptide (KKHTDDGYMPMSPGVA) and 20 mM Tris, pH 7.6, 10 mM MgCl 2 , 15 M ATP, and 5 Ci of [␥-
32 P]ATP. After 20 min at 24°C, reactions were terminated by the addition of 100 l of buffer U (125 mM Tris, pH 6.8, 6 M urea), and the samples were electrophoresed on 40% PAGE. Phosphorylated peptide bands were identified by autoradiography, excised, and counted. HEK 293/IRS cells were treated with or without 1.6 M PMA for 20 min and lysed in lysis buffer A. Lysates were incubated with anti-ERK2 antibodies coupled to agarose for 2 h, the beads were washed three times in WGB, and then the bound ERK2 was incubated with varying concentrations of IRS-1 peptide and 100 l of kinase buffer (20 mM Tris, pH 7.6, 10 mM MgCl 2 , 15 M ATP, and 5 Ci of [␥-32 P]ATP) for 20 min at 24°C. One hundred l of buffer U were added to the peptide-containing supernatants, and the samples were analyzed as described for cytosolic lysates.
Coprecipitation of IRS-1 and ERK2-293/IRS cells and 293T cells transfected with IRS-Myc and ER-Raf were treated with and without either 1.6 M PMA or 1 M 4-HT, respectively and lysed, and the lysates were immunoprecipitated with anti-Myc antibodies bound to protein G-agarose for 2 h. IRS-1 immunoprecipitates were either incubated with 100 l of kinase mix with or without 100 M IRS-1 peptide as described above or analyzed by 10% SDS-PAGE, followed by transfer to Immobilon and Western blotting with antibodies to ERK2. Blots were stripped and probed with antibodies to IRS-1. IRS-1 beads that had been incubated with kinase mix and peptide were microcentrifuged; peptide-containing supernatants were added to 100 l of buffer U and analyzed by electrophoresis on 40% PAGE, and IRS-1 beads were washed and analyzed by electrophoresis on 7.5% SDS-PAGE and transferred to Immobilon. Phosphorylation was determined by autoradiography. Membranes were probed with antibodies to IRS-1, and either IRS-1 bands or peptide bands were excised and counted.
In Gel Kinase Assays-Confluent 10-cm plates of 293/IRS cells were treated with or without 1.6 M PMA for 20 min following overnight serum starvation, lysed in 200 l of 1% SDS, PBS, passaged 10 times through an 18-gauge needle followed by 10 passages through a 21-gauge needle. Equal volumes of SDS loading buffer were added, and samples were boiled for 5 min and analyzed on 10% SDS-PAGE gels containing either 0.1 mg/ml glutathione transferase or GST-IRS-1B/R. Gels were soaked for 4 h in 40 mM Hepes containing 2% isopropanol to remove SDS. Gels were incubated for 1 h in 30 ml of reaction buffer containing 20 mM Hepes, 10 mM MgCl 2 , and 1 Ci/ml [␥-
32 P]ATP. Gels were washed three times in 40 mM Hepes for 1 h, followed by 1% Na-PP i in 5% trichloroacetic acid for 1 h, stained 10 min with Coomassie Blue in 25% MeOH, 10% acetic acid, destained overnight, dried, and autoradiographed.
Detection of Activated MAP Kinase-Confluent 10-cm plates of 293/ IRS cells were treated with 1.6 M PMA for 20 min, or 3T3-L1 cells stably expressing ⌬Raf:ER were treated with 1 M 4-HT for 1 h. Cells were lysed as described previously; 10-l samples (corresponding to 1/50 of a plate) were analyzed on 12.5% SDS-PAGE followed by transfer to Immobilon and immunoblotting with anti-active MAP kinase antibodies (Promega).
RESULTS
PKC Activation Inhibits Insulin-stimulated Tyrosine Phosphorylation of IRS-1 and Association with PI 3-Kinase-Human embryonic kidney cells (293 cells) stably expressing a
Myc-tagged IRS-1 (16) were pretreated with or without 1.6 M PMA followed by stimulation with or without insulin. Cell lysates were immunoprecipitated with antibodies to p85 and analyzed by SDS-PAGE followed by transfer to Immobilon and immunoblotting with an anti-phosphotyrosine antibody. Insulin stimulated a 4.5 Ϯ 0.5-fold (n ϭ 3) increase in the amount of tyrosine-phosphorylated proteins associated with p85 (Fig. 1A,  lanes 1 and 2) . Several proteins with a mass ϳ180 kDa were found associated with p85 as well as a 95-kDa protein. The same blot was stripped and reprobed with an antibody to the Myc epitope. Two of the proteins migrating at 180 kDa (the lower two bands of the triplet) as well as the 95-kDa protein were found to react with this antibody, indicating that all three of these bands were derived from the expressed IRS-1, possibly due to degradation (data not shown). The highest molecular weight band is presumably endogenous IRS-1,2 or the recently described IRS-4 present in these cells, since it did not react with the antibodies to Myc (23) . Pretreatment of the cells with an activator of PKC, PMA, inhibited by 60 Ϯ 5% (n ϭ 3) the insulin-stimulated increase in the association of all four of these tyrosine-phosphorylated proteins with p85, indicating that PKC activation inhibited the tyrosine phosphorylation of both the expressed IRS-1 as well as the endogenous IRS protein (Fig. 1A, lanes 2 and 3) . Finally, the membranes were reprobed with an antibody to p85 (Fig. 1B) to verify that the amounts of p85 precipitated under the different conditions were comparable. Thus, these results indicate that PKC activation inhibits tyrosine phosphorylation of IRS-1 at residues necessary for p85 binding.
IRS-1 Is Phosphorylated by ERK2 in Vitro-
In previous studies, we had established that PKC activation stimulated a cytosolic kinase capable of phosphorylating both full-length IRS-1 and a peptide (KKHTDDGYMPMSPGVA) corresponding to IRS-1 residues 603-616, with two additional basic residues at the N terminus (16) . To determine whether MAP kinase is capable of phosphorylating both full-length IRS-1 and this peptide, we first activated recombinant ERK2 in vitro with recombinant MEK. Inactive and active ERK2 were incubated with full-length IRS-1 immunoprecipitated from 293-IRS cells ( Fig.  2A, lanes 1 and 2) , or with the IRS-1 peptide (Fig. 2A, lanes  3-5) , in the presence of [ 32 P]ATP. Phosphorylated IRS-1 was then analyzed by SDS-PAGE followed by transfer to Immobilon, and peptide samples were analyzed by electrophoresis on 40% polyacrylamide gels. Phosphorylation by MAP kinase was visualized by autoradiography and IRS-1 bands, or peptide bands were excised and counted. Addition of active ERK2 resulted in a 10-fold stimulation of IRS-1 phosphorylation and a 20-fold stimulation of peptide phosphorylation. Controls of IRS-1 incubated with the same amount of active MEK alone exhibited no increase in phosphorylation (data not shown).
Having established that recombinant ERK2 is capable of phosphorylating IRS-1, we next investigated whether or not endogenous ERK2 was stimulated after activation of PKC in 293 cells. 293/IRS cells were treated with or without PMA, and cell lysates were analyzed by SDS-PAGE and immunoblotting with an antibody that specifically recognizes active ERK1 and 2. PMA treatment was found to rapidly stimulate the formation of active ERK1 and 2 in these cells (Fig. 2B) . To further confirm the activation of ERK and to verify whether it could phosphorylate the IRS-1 peptide, the lysates from PMA-treated and control cells were immunoprecipitated with an antibody to ERK2. These immunoprecipitates were then incubated with increasing concentrations of the IRS-1 peptide and [␥-32 P]-ATP. Peptide samples were analyzed by electrophoresis on 40% polyacrylamide gels followed by autoradiography, and bands were excised and counted. These experiments showed that PMA stimulated a 10-fold increase in the ability of endogenous ERK2 to phosphorylate the IRS-1 peptide (Fig. 2C) .
To further assess whether PMA-treatment stimulates MAP kinase which then phosphorylates IRS-1, we made a GST fusion protein containing residues 509 -890 of IRS-1 (this includes the four putative MAP kinase phosphorylation sites) and utilized this fusion protein in an in gel kinase assay. PMA treatment was found to greatly stimulate the ability of two kinases of 40 -45 kDa to phosphorylate the GST IRS-1B/R fusion protein (Fig. 2D) . The position of these two kinases on the SDS gel were identical to the activated ERKs (Fig. 2B) . No comparable bands were observed in parallel gels containing the control GST. These results indicate that the major renaturable kinases capable of phosphorylating this IRS-1 fusion protein are likely to be ERK1 and 2.
These results are consistent with the hypothesis that activation of PKC in 293 cells stimulates MAP kinase which phosphorylates IRS-1. If such a phosphorylation event were responsible for the observed PKC-mediated inhibition of insulin signaling (Fig. 1) , we would expect that the ability of IR to tyrosine-phosphorylate IRS-1 to be inhibited by prior MAP kinase phosphorylation. To test this hypothesis, IRS-1 was immunoprecipitated from 293/IRS cells and then incubated with or without activated recombinant ERK2. The IRS-1-containing beads were then washed and incubated either with or without activated IR prepared from PMA-treated 293 cells. IR from cells pretreated with PMA was utilized, since prior studies have shown that these receptors have a lesser ability to phosphorylate in vitro IRS-1 from PMA-pretreated cells then does IR from nontreated cells, suggesting that PKC activation stimulates Ser/Thr phosphorylation of both IR and IRS-1, and this acts synergistically to impede IRS-1 tyrosine phosphoryl- 1 and 2) or 100 M IRS-1 peptide (lanes 3-5) were incubated with 1 g of either inactive or activated recombinant ERK2 as indicated. After the phosphorylation reaction, samples were analyzed by either electrophoresis on 7.5% SDS-PAGE, transfer to Immobilon, and autoradiography (lanes 1 and 2) or by electrophoresis on 40% PAGE and autoradiography (lanes 3-5) . B, 6 M PMA were lysed, and the lysates were electrophoresed on a 10% SDS-PAGE containing 0.1 mg/ml of GST-IRS-1B/R. After renaturation, the kinase reaction was performed, and the gels were stained, destained, and autoradiographed. E, ERK2 phosphorylation of IRS-1 inhibits subsequent tyrosine phosphorylation by IR as assessed by p85 SH2 binding. IRS-Myc immunoprecipitates from 293/IRS cells, preincubated with or without 1 g of activated ERK2, were washed and incubated with or without activated IR. Samples were analyzed by 7.5% SDS-PAGE, transferred to Immobilon, and probed with a complex of GST-p85 and anti-GST antibody, followed by secondary antibody coupled to horseradish peroxidase and enhanced chemiluminescence. unt, untreated samples.
FIG. 2. IRS-1 can be phosphorylated in vitro by ERK2, and this phosphorylation inhibits subsequent tyrosine phosphorylation and association with p85 SH2 domains. A, phosphorylation of intact IRS-1 and IRS-1 peptide (pep) by recombinant ERK. Intact IRS-Myc immunoprecipitated from 293/IRS cells (lanes
ation by IR (16) . Samples were analyzed by SDS-PAGE, transferred to Immobilon, and probed with a glutathione S-transferase fusion protein containing the SH2 domains of p85. The bound p85 was detected with an antibody to GST. Incubation of IRS-1 with activated IR results in a 10 Ϯ 1-fold (n ϭ 4) increase in p85 binding (Fig. 2E) . When IRS-1 that had first been phosphorylated by ERK2 was incubated with IR, only a 5 Ϯ 0.3-fold (n ϭ 4) increase in p85 binding was observed (Fig. 2E) . These results indicate that the prior phosphorylation of IRS-1 by ERK2 in vitro directly interferes with the ability of IR from PMA-treated cells to phosphorylate IRS-1 on a tyrosine which is involved in binding the SH2 domains of PI 3-kinase.
Activation of ERK1 and 2 via a Regulatable Raf Results in Inhibition of Insulin-stimulated Tyrosine Phosphorylation of IRS-1-
To establish whether activation of MAP kinase was sufficient to inhibit insulin-stimulated tyrosine phosphorylation in vivo, we used a tamoxifen-activable Raf:ER fusion protein containing the hormone binding domain of a mutant estrogen receptor (24) (which binds tamoxifen but not estrogen) and the kinase domain of B-Raf (⌬Raf-1:ER) (20) . Expression of this protein in mammalian cells has been shown to result in activation of ERK1 and 2 in response to the estrogen analog, 4-HT (25) , and this was verified in the present studies (Fig. 2B and data not shown). Because Raf does not activate other subfamilies of MAP kinases such as stress-activated protein kinases and p38 MAP kinase, whereas other upstream activators of ERKs, such as growth factors and Ras, activate multiple MAP kinase pathways, use of the ⌬Raf-1:ER fusion protein allows us to specifically investigate the effects of activating ERK1 and 2 on insulin signaling (17) (18) (19) .
293T cells were transiently cotransfected with IRS-Myc and ⌬Raf-1:ER. After overnight serum starvation, cells were treated with or without 1 M 4-HT for 2 h, followed by treatment with or without 1 M insulin for 5 min. Cell lysates were immunoprecipitated with anti-Myc antibodies and the precipitates were analyzed by SDS-PAGE, transferred to Immobilon, and probed with anti-phosphotyrosine antibodies. While insulin stimulates tyrosine phosphorylation of transfected IRS-Myc (Fig. 3A, lane 2 versus 1) , pretreatment with 4-HT inhibits subsequent insulin-stimulated tyrosine phosphorylation by 50 Ϯ 7% (n ϭ 4) (Fig. 3A, lane 3 versus 2) . Furthermore, treatment of 293T cells transiently transfected with ⌬Raf-1:ER with tamoxifen resulted in a 5.5-fold increase in the ability of the cytosolic fraction to phosphorylate the IRS-1 peptide described above (Fig. 3B) .
To study the MAP kinase regulation of insulin-stimulated tyrosine phosphorylation of IRS-1 in a more physiological system, we also established a stable cell line expressing ⌬Raf-1:ER in 3T3-L1 cells (3T3-L1/Raf:ER). 3T3-L1 cells can be differentiated into adipocytes, a physiological target for insulin, and they express high levels of endogenous insulin receptor and are insulin-responsive (26) . 3T3-L1/Raf-1:ER cells were differentiated and serum-starved overnight. Adipocytes were either pretreated or not with 1 M 4-HT for 2 h, followed by treatment with or without 1 M insulin for 5 min. Lysates were immunoprecipitated with antibodies to p85, analyzed by SDS-PAGE, transferred to Immobilon, and probed with anti-phosphotyrosine antibodies. Insulin stimulated the association of tyrosine phosphorylated IRS-1 with p85, and pretreatment with 4-HT inhibited insulin-stimulated p85/IRS-1 association by 62 Ϯ 8% (n ϭ 3) (Fig. 3A, lanes 4 -6) . These studies demonstrate that activation of ERK1 and 2 alone is sufficient in vivo to inhibit insulin-stimulated tyrosine phosphorylation of IRS-1 and subsequent association with p85.
PKC-mediated Inhibition of IRS-1/PI 3-Kinase Association Is Dependent on Activation of ERK1 and 2-If activation of
ERK1 and 2 is the mediator of PKC-induced insulin resistance, than inhibition of ERK1 and 2 activation should prevent the inhibitory effect of PKC activation. To test this hypothesis, we used the compound PD98059, a reversible inhibitor of MEK1, the enzyme that directly activates ERK1 and 2 (27) . 293/IRS cells were serum-starved overnight, after which they were treated with or without 50 M PD98059, followed by treatment with or without PMA and stimulation with or without insulin. Cell lysates were immunoprecipitated with anti-Myc antibody, and IRS-1-associated PI 3-kinase activity was assayed as described previously. While insulin stimulated IRS-1 associated PI 3-kinase activity 6-fold, pretreatment with PMA inhibited the insulin-stimulated increase in PI 3-kinase activity by 60 Ϯ 3% (n ϭ 9) (Fig. 4, lanes 1-3) . Finally, when cells were treated with the MEK1 inhibitor, PD98059, before PMA treatment, insulin stimulation of IRS-1-associated PI 3-kinase activity was comparable to that in cells which had not been pretreated with PMA, and a 6-fold stimulation was observed (Fig. 4A , lane 4) (n ϭ 9). These results indicate that the PMA-mediated inhibition of insulin-stimulated IRS-1 tyrosine phosphorylation and PI 3-kinase association is dependent upon activation of MEK1, a specific activator of ERK1 and 2.
PD98059 was also tested for its ability to prevent the activation of the cytosolic kinase using the peptide assay described above. When cells were pretreated with PD98059, the PMAstimulated increase in peptide phosphorylation was significantly inhibited (Fig. 4B, lanes 1-3) . A specific inhibitor of p38 MAP kinase, SB203580 (28), was also tested for its ability to inhibit the PMA-induced kinase activity, since p38MAP kinase has been shown to be activated by PMA in some systems. Pretreatment of cells with SB203580 had no effect on the PMA-induced cytosolic IRS-1 peptide kinase activity (Fig. 4B,  lane 4) , indicating that p38 MAP kinase was not responsible for this activity.
ERK2 Activity Is Associated with IRS-1 upon PKC Activation-Since MAP kinase is sometimes found in association with its substrates (29), we tested whether IRS-1 was associated with this enzyme. 293/IRS cells were treated with or without PMA and lysed, and the lysates were immunoprecipitated with anti-Myc antibodies. The immunoprecipitates were washed twice with HBS, 0.1% Triton X-100, and then the IRS-1-con- taining beads were incubated with or without the IRS-1 peptide in the presence of [␥-32 P]ATP. Peptide-containing supernatants were analyzed by electrophoresis on a 40% polyacrylamide gel, and IRS-1 beads were washed and analyzed by SDS-PAGE, followed by transfer to Immobilon and autoradiography. IRS-1 immunoprecipitated from PMA-treated cells (but not nontreated cells) was phosphorylated without the addition of exogenous kinase (Fig. 5A) , and this phosphorylation was inhibited by the presence of the IRS-1 peptide (Fig. 5A) . Moreover, peptide incubated with IRS-1 from PMA-treated, compared with untreated, cells exhibited a 3-fold increase in phosphorylation (Fig. 5B) . Finally, to determine whether ERK2 was associated with IRS-1, we treated 293/IRS cells with and without PMA and lysed the cells. The cell lysates were immunoprecipitated with anti-Myc antibodies, analyzed by SDS-PAGE, transferred to Immobilon, and probed with antibodies to ERK2. PMA treatment stimulated an increase in the association of ERK2 with IRS-1 (Fig. 5C) . Similarly, 293T cells were transfected with IRS-Myc and ⌬Raf-1:ER, treated with or without 4-HT, and lysed. The lysates were immunoprecipitated with anti-Myc antibodies, analyzed by SDS-PAGE, transferred to Immobilon, and probed with antibodies to ERK 2. HT treatment also stimulated an increase in association of ERK2 with IRS-1 (Fig. 5C ). These results suggest that, upon activation, ERK2 associates with IRS-1.
DISCUSSION
Prior studies have indicated that increased Ser/Thr phosphorylation of IRS-1 stimulated by a variety of factors interferes with both the ability of this molecule to be tyrosine-phosphorylated after insulin treatment and its ability to subsequently associate with the PI 3-kinase (7-12). Recent studies have implicated several serines in the IRS-1 molecule with this inhibitory response, including serines 612, 632, 662 and/or 731 (16, 30) . All 4 of these serine residues are in the consensus motif for MAP kinase phosphorylation sites (15) . In the present studies we provide evidence that MAP kinase can phosphorylate IRS-1 and is involved in the subsequent inhibition of insulin signaling. First, we have demonstrated that both recombinant ERK2 and ERK2 immunoprecipitated from PMA-treated 293/IRS cells have the ability to phosphorylate both full-length IRS-1 and a synthetic peptide corresponding to the serine 612 of IRS-1 (Fig. 2, A and C) . Second, we show that the major renaturable kinases in cell lysates from PMA-treated cells which can phosphorylate an IRS-1 fusion protein (containing residues 509 -890) comigrate with ERK1 and 2 (Fig. 2D) . Third, the phosphorylation of IRS-1 by recombinant ERK2 inhibits the ability of the IR to phosphorylate IRS-1 at sites that allow the binding of the p85 SH2 domains (Fig. 2B) . Thus, the phosphorylation of IRS-1 in vitro by recombinant ERK2 results in an inhibition of insulin signaling, which parallels that observed in intact cells that have been treated with PMA (Fig. 1) . Fourth, PKC-induced inhibition of insulin signaling is mimicked in vivo when an activable Raf construct (⌬Raf-1:ER) is utilized to specifically activate ERK1 and 2 (Fig. 3) . Fifth, a specific inhibitor of MEK1, PD98059, blocked the ability of PMA-pretreatment to inhibit insulin signaling (Fig. 4A ). This compound also inhibited the ability of PMA to stimulate the activation of the cytosolic IRS-1 peptide kinase, whereas an inhibitor of the p38MAP kinase pathway was unable to inhibit the activation of this kinase (Fig. 4B) . Finally, the immunoprecipitation of IRS-1 from PMA-treated cells resulted in the coprecipitation of an enzymatically active ERK2 (Fig. 5) . Taken together, these results strongly support the hypothesis that MAP kinase is at least partly responsible for the phosphorylation of IRS-1 in PMA-treated cells, which results in its subsequent decreased ability to be tyrosine-phosphorylated at sites responsible for its interaction with PI 3-kinase. The present studies do not, however, rule out the possibility that other Ser/Thr kinases may phosphorylate IRS-1 under other conditions and also lead to an inhibition of insulin signaling.
It should be noted that prior studies have also noted a potential role for MAP kinase in a feedback inhibition of insulin signaling. For example, some studies have indicated that the MAP kinases may be involved in the serine/threonine phosphorylation of SOS, resulting in the disassociation of the Grb2⅐SOS complex, and thereby limiting the extent of Ras activation (31) (32) (33) . In addition, a decrease in insulin signaling was noted in brown fat cells overexpressing Ras, a condition which would activate the MAP kinase (34) . It has also been recently reported that long term treatment with insulin potentiates activation of p21Ras by growth factors, a finding that is consistent with the hypothesis that hyperinsulinemia could lead to insulin resistance by increasing MAP kinase activation (35) . Finally, it has been observed in at least one model of obesity, the ob/ob mouse, that there is an elevated level of basal MAP kinase activity (36) . This observation is consistent with our previous identification of an increase in the levels of the cytosolic IRS-1 peptide serine kinase (i.e.. MAP kinase) in the livers of ob/ob mice (16) .
